Key Takeaways Rigel stock has jumped 76.7% in three months, fueled by strong momentum for Tavalisse.Tavalisse made up over 65% of net product sales in Q2 2025, the firm's best quarter yet.Rigel raised 2025 revenue guidance to $270-$280M, led by Tavalisse, Rezlidhia and Gavreto.Shares of Rigel Pharmaceuticals (RIGL) have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s lead drug, Tavalisse (fostamatini ...